SCHEMBL324589

SCHEMBL324589

Cc1cccc(COC(=O)N2C=Cc3ccccc3C2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 1/20 0.41
POLB P06746 2/20 0.41
MMP2 P08253 1/20 0.40
MMP9 P14780 1/20 0.40
MMP12 P39900 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
P2RX4 Q99571 1/20 0.40
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
ALDH1A1 P00352 1/20 0.38
MAOB P27338 2/20 0.38
IDO1 P14902 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
TMEM97 Q5BJF2 2/20 0.37
SIGMAR1 Q99720 2/20 0.37
HTR1A P08908 1/20 0.36
ADRA2A P08913 1/20 0.36
ADRA2B P18089 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL324346 0.88 P2RX4 (0.47) GRIN2BMMP2MMP9MMP12NPSR1
SCHEMBL324299 0.86 P2RX4 (0.52) NPSR1P2RX4MEN1KMT2AL3MBTL1
SCHEMBL323321 0.86 NPC1 (0.47) MMP2MMP9MMP12P2RX4ALDH1A1
SCHEMBL325206 0.86 HCAR2 (0.43) MMP2MMP9MMP12P2RX4MEN1
SCHEMBL323355 0.86 HCAR2 (0.43) GRIN2BMMP2MMP9MMP12P2RX4
SCHEMBL323429 0.83 PRKCA (0.46) MMP12MEN1KMT2AMAOBIDO1
SCHEMBL324049 0.83 FFAR1 (0.40) P2RX4MAOB
SCHEMBL324992 0.83 NPSR1 (0.37) GRIN2BNPSR1P2RX4MEN1KMT2A
SCHEMBL323497 0.82 HSD17B3 (0.37) POLBNPSR1P2RX4MEN1KMT2A
SCHEMBL15056964 0.82 HDAC3 (0.41) GRIN2BPOLBNPSR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590944-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2013-05-15 EP disclosed
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2013-05-02 US disclosed
WO-2012004722-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS PTGER1, PTGDR, PTGDR2 GRIN2B 1330/4885POLB 3630/4885MMP2 3105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.